Transition to endemic: acceptance of additional COVID-19 vaccine doses among Canadian adults in a national cross-sectional survey

BMC Public Health, Journal Year: 2022, Volume and Issue: 22(1)

Published: Sept. 14, 2022

Abstract Background Additional doses of COVID-19 vaccine have been proposed as solutions to waning immunity and decreased effectiveness primary against infection with new SARS-CoV-2 variants. However, the additional relies on widespread population acceptance. We aimed assess acceptance (third annual doses) among Canadian adults determine associated factors. Methods conducted a national, cross-sectional online survey from October 14 November 12, 2021. Weighted multinomial logistic regression analyses were used identify sociodemographic health-related factors third dose indecision, compared refusal. also assessed influences decision-making, preferences for future delivery. Results Of 6010 respondents, 70% reported they would accept dose, while 15.2% undecided. For doses, 64% acceptance, 17.5% Factors indecision similar those indecision. Previous receipt, no history disease, intention receive an influenza vaccine, increasing age strongly both Chronic illness was higher odds self-reported disability being Higher education attainment income accepting doses. Minority first language undecided about visible minority identity refusing dose. All respondents government recommendations important influence their decision-making identified pharmacy-based delivery drop-in appointments desirable. Co-administration vaccines viewed positively by 75.5% 3 group, 12.3% 8.4% refusal group. Conclusions To increase targeted interventions populations, disability, are required. Offering vaccination at pharmacies through facilitate uptake, offering COVID-19/influenza co-administration may little benefit

Language: Английский

---

COVID-19 Vaccine Booster Hesitancy in Malaysia: A Web-Based Cross-Sectional Study

Vaccines, Journal Year: 2023, Volume and Issue: 11(3), P. 638 - 638

Published: March 13, 2023

Vaccination is a key public health strategy that known to be effective in mitigating the risk of infection and severe disease. However, context COVID-19 pandemic, percentage (<50%) Malaysians who have received booster for vaccine has remained stagnant over year. This study aimed determine prevalence factors associated with hesitancy toward second dose vaccine. A web-based cross-sectional was conducted from August November 2022. The Oxford Vaccine Hesitancy Scale used assess Simple multiple logistic regressions were predictors hesitancy. p-value less than 0.05 considered statistically significant. Data 798 respondents included analysis. 26.7%. second-booster older age (AOR = 1.040, 95 CI 1.022, 1.058), having third (first booster) because instruction by government 2.125, 95% 1.380, 3.274), concern about serious long term side effects 4.010, 2.218, 7.250), opinions close friends immediate family members harmful 2.201, 1.280, 3.785). Conversely, appear reduce acceptance due high number cases increasing rate 0.548, 0.317, 0.947), belief will decrease getting 0.491, 0.277, 0.870), helpful 0.479, 0.273, 0.840). In conclusion, more one-fifth hesitant take suggests appropriate steps increase acceptance, taking into consideration findings present study, are needed address this issue foster positive attitudes vaccination. survey available three main languages but limited people internet access; hence, it would likely biased younger adults social media users exclude those or no access, particular people. Therefore, results not representative Malaysian population at large caution should exercised when interpreting findings.

Language: Английский

---

Hesitancy toward vaccination against COVID-19: A scoping review of prevalence and associated factors in the Arab world

Human Vaccines & Immunotherapeutics, Journal Year: 2023, Volume and Issue: 19(2)

Published: Aug. 1, 2023

Despite widespread availability of vaccines against SARS-CoV-2 virus, the cause Coronavirus Disease 2019 (COVID-19), its uptake in many Arab countries is relatively low. This literature review aimed to scope evidence on COVID-19 vaccine hesitancy (VH) world. A total 134 articles reporting prevalence VH and associated factors, conducted any 22 League countries, were reviewed. ranged from 5.4% 83.0%. Female gender, young age, low education level lack previous influenza most commonly reported be with VH. The most-reported personal concerns contributing toward related rapid development, safety side effects vaccine, as well an overall trust government policies pandemic control conspiracy theories. Tailored interventions enable distribution trusted information enhance public acceptance immunization are warranted.

Language: Английский

---

Prevalence and factors associated with not receiving the booster dose of the COVID-19 vaccine in adults in Latin America and the Caribbean

Travel Medicine and Infectious Disease, Journal Year: 2022, Volume and Issue: 50, P. 102409 - 102409

Published: Aug. 9, 2022

Language: Английский

---

Prevalence and Motivators of Getting a COVID-19 Booster Vaccine in Canada: Results from the iCARE Study

Vaccines, Journal Year: 2023, Volume and Issue: 11(2), P. 291 - 291

Published: Jan. 28, 2023

Studies have shown that the protection afforded by COVID-19 vaccines against hospitalization and death decreases slowly over time due to emergence of new variants waning immunity. Accordingly, booster doses remain critical minimizing health impacts pandemic. This study examined prevalence rate, sociodemographic determinants, motivators getting a vaccine within Canadian population. We recruited representative sample 3001 Canadians aged 18+ years as part iCARE using an online polling form between 20 January 2 February 2022. Participants self-reported their status were dichotomized into two groups: those who did vs. not receive at least one dose. A total 67% participants received Chi-square analyses revealed older age (p < 0.001) having chronic disease diagnosis associated with being more likely get booster. Boosted individuals reported tied efficacy altruism, whereas non-boosted safety. Results suggest messaging will require careful tailoring address identified behavioral among emphasize safety additional doses.

Language: Английский

---